Table 1 Overview of ongoing clinical trials of adoptive NK cell transfer in AML
From: Natural killer cell-based immunotherapy for acute myeloid leukemia
Identifier | Phase | Indication | In vivo cytokine | Transplantation | Outcome measure |
|---|---|---|---|---|---|
PBMC-derived NK cell infusion | |||||
 NCT04221971 | I | R/R AML | None | No | AE, response, NK cell metabolism, migration and reconstruction, cell count recovery, relapse |
 NCT04220684 | I | R/R AML or MDS | None | No | MTD, AE, response, survival, cell count recovery, number of patients able to proceed to HCT |
 NCT04209712 | I | AML with MRD | IL-2 | No | MRD, AE |
 NCT02890758 | I | AML, MDS, et al | ALT-803 | No | AE, response, survival, in vivo NK level |
 NCT01787474 NCT02809092 | I/II | R/R AML | None | No | MTD, response, NK cell expansion |
 NCT03300492 | I/II | AML or MDS | None | Days + 10, + 15 and + 20 post-HCT | AE, survival, response, NK cell dose |
 NCT01823198 | I/II | High-risk AML or MDS | IL-2 | Day -8 pre-HCT | Optimal NK cell dose, survival, AE |
 NCT01904136 | I/II | AML, MDS or CML | None | Days 7 and 28–90 post-HCT | MTD, AE, survival, time to engraftment |
 NCT04395092 | II | High-risk AML or MDS | None | Days—2, + 7 and + 28 post-HCT | Relapse, AE, survival |
 NCT04166929 | II | AML or MDS | None | Day + 7 post-HCT | Relapse |
 NCT03050216 | II | R/R AML | ALT-803 | No | Response, NK cell expansion, AE |
 NCT03955848 | NA | AML in remission | IL-2 | No | Survival |
Placental-derived HSPC-NK cell (CYNK-001) infusion | |||||
 NCT04310592 | I | AML | None | No | MTD, AE, MRD, survival |
UCB-derived HSPC-NK cell infusion | |||||
 NCT01619761 | I | AML, MDS, et al | None | Day-2 pre-CBT | AE, survival |
 NCT04347616 | I/II | R/R AML | IL-2 | No | AE, MRD, NK cell lifespan, expansion and functional activity, plasma cytokine concentration, number of patients able to proceed to HCT |
 NCT02727803 | II | AML, MDS, et al | None | Days 30–180 post-CBT | Survival, AE |
iPSC-derived NK cell (FT516) infusion | |||||
 NCT04023071 | I | R/R AML or B-cell lymphoma | IL-2 | No | AE, response, pharmacokinetic data |
Cytokine-induced memory-like NK cell infusion | |||||
 NCT03068819 | I | Relapsed AML after HCT | None | No | AE, response, survival |
 NCT04024761 | I | Relapsed AML, MDS or MPN after HCT | IL-2 | No | AE, response, survival |
 NCT01898793 | I/II | R/R AML or MDS | IL-2 | No | MTD, response, AE, survival |
 NCT04354025 | II | R/R AML | IL-2 | No | Response, number of patients able to proceed to HCT, survival, MRD, AE |
 NCT02782546 | II | R/R AML | ALT-803 | Day + 7 post-HCT | Survival, response |
CMV-induced memory-like NK cell (FATE-NK100) infusion | |||||
 NCT03081780 | I | R/R AML | IL-2 | No | MTD, response, NK cell expansion, AE, MRD, survival |